Stem Cell Therapeutics to Provide Update on CD47 Program at the 2013 Annual Meeting of the American Society of Hematology
December 05 2013 - 6:00AM
Marketwired
Stem Cell Therapeutics to Provide Update on CD47 Program at the
2013 Annual Meeting of the American Society of Hematology
TORONTO, ONTARIO--(Marketwired - Dec 5, 2013) - Stem Cell
Therapeutics Corp. (TSX-VENTURE:SSS) (OTCQX:SCTPF), an
immuno-oncology company developing cancer stem cell-related
therapeutics, today announced it will be providing an update on its
immune checkpoint program targeting the CD47 protein at the 55th
Annual Meeting of the American Society of Hematology, which will be
held December 7-10, 2013 in New Orleans, LA. Details of the poster
presentation, entitled "Blockade of CD47 Using SIRPaFc: Role of
the Fc Region in Anti-Leukemic Activity", are listed
below:
Date: |
Monday December 9, 2013 |
Time: |
6:00 - 8:00 pm (CST) |
Session: |
615. Acute Myeloid Leukemia: Therapy,
excluding Transplantation: Poster III |
Abstract #: |
3935 |
Presenter: |
Dr. Robert Uger, Chief Scientific
Officer |
Location: |
Hall E, Ernest N. Morial Convention Center,
New Orleans, LA |
About Stem Cell
Therapeutics:
Stem Cell
Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and
groundbreaking Canadian stem cell research, the company is
supported by established links to a group of prominent Toronto
academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research
hubs. The Company has two premier preclinical programs, SIRPaFc and
a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the
host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is
a fully human monoclonal antibody that blocks the activity of
CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. SCT's clinical stage programs
include the recently in-licensed program focused on the structure
of tigecycline, which is currently being evaluated in a
multi-centre Phase I study in patients with acute myeloid leukemia
(AML), as well as TTI-1612, a non- cancer stem cell asset that
recently completed a 28-patient Phase I trial in interstitial
cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Stem Cell Therapeutics Corp.James ParsonsChief Financial
Officer+1 416 595
0627jparsons@stemcellthera.comwww.stemcellthera.comInvestor
Contact:Jeff Ramson/Kirin SmithProActive Capital+1
646-863-6519jramson@proactivecapital.comksmith@proactivecapital.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Sunvest Minerals Corp (TSX Venture Exchange): 0 recent articles
More Stem Cell Therapeutics Corp. News Articles